Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ia bukan cadangan pelaburan.
Perihal
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Bergantung pada bursa, simbol saham mungkin berbeza. Sebagai contoh, di bursa Boerse Muenchen, saham Rubius Therapeutics didagangkan di bawah simbol 5RT.MU.
Berapa ramai pekerja yang dimiliki oleh Rubius Therapeutics?▼
Sehingga Julai 19, 2026, syarikat mempunyai 213 pekerja.
Rubius Therapeutics terletak dalam sektor apa?▼
Rubius Therapeutics beroperasi dalam sektor Teknologi.